X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will also be used to advance pipeline programs through clinical development and further fund Apollo’s drug discovery and development activities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $260.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 02, 2024
Details:
The proceeds will be used to advance pipeline programs through clinical development and further fund Apollo’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $226.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 06, 2023
Details:
Apollo Therapeutics is advancing a pipeline of therapeutic programmes based on breakthrough discoveries. The company identifies and develops pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful new treatment options.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: ICR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 28, 2022
Details:
The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Institute of Cancer Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 14, 2022
Details:
Under the terms of the agreement, Apollo will assume responsibility for the future development of AVTX-007 (camoteskimab), including the ongoing clinical trial. Apollo will lead future clinical development in its selected therapeutic indications.
Lead Product(s): AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVTX-002
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Avalo Therapeutics
Deal Size: $89.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement August 01, 2022
Details:
Proceeds from the investment will support advancement of Apollo's robust pipeline into development, expansion of the company's operations including establishment of a presence in the Boston, MA area and pursuit of new collaborations globally.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $145.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
